SomaLogic to Announce Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023 16:30 ET
|
SomaLogic
BOULDER, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022...
SomaLogic announces Certified Site expansion through world-class multiomics initiative with Group 42 Healthcare
January 31, 2023 09:00 ET
|
SomaLogic, Inc
BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program...
SomaLogic Announces Preliminary Full Year 2022 Revenue and Provides Organizational and Strategic Updates
January 09, 2023 09:00 ET
|
SomaLogic, Inc
BOULDER, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that preliminary, unaudited revenue for the full year 2022 is expected to be at...
SomaLogic to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 29, 2022 16:30 ET
|
SomaLogic Operating Company, Inc.
BOULDER, Colo., Dec. 29, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan...
FonesLife offers the 7,000-plex SomaScan® Platform as Japan’s first SomaLogic™ Certified Site
December 19, 2022 08:00 ET
|
SomaLogic Operating Company, Inc.
TOKYO and BOULDER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomic technology, announced today that Tokyo-based FonesLife Corporation, will be the first SomaLogic™...
Proteomics labs worldwide can now access SomaLogic’s industry-leading 7,000-plex SomaScan® Assay with the Certified Site program
December 07, 2022 11:28 ET
|
SomaLogic Operating Company, Inc.
BOULDER, Colo., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today the full-scale global launch of the SomaLogic™ Certified Site program, which...
Study finds proteomic risk scores for cardiovascular disease from SomaSignal® Cardio DM™ tests could support physicians in managing patient outcomes
November 17, 2022 08:00 ET
|
SomaLogic Operating Company, Inc.
BOULDER, Colo., Nov. 17, 2022 (GLOBE NEWSWIRE) -- In an upcoming randomized, controlled study enrolling 248 physicians, researchers are measuring whether SomaLogic’s SomaSignal® tests aid physicians...
SomaLogic Reports Third Quarter 2022 Financial Results
November 14, 2022 08:00 ET
|
SomaLogic Operating Company, Inc.
Third quarter 2022 revenue of $41.7 million, bringing year to date revenue to $78.8 million.Core life science revenue of $20.5 million, representing an increase of 2.9% year-over-year and 45.4%...
SomaLogic Teams with Molecular Genomics to Bring the 7,000-Plex SomaScan® Platform to Asia
November 08, 2022 08:00 ET
|
SomaLogic Operating Company, Inc.
SINGAPORE and BOULDER, Colo., Nov. 08, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that Singapore-based Molecular Genomics, a Genomax Technologies...
SomaLogic presents new research at American Heart Association Scientific Sessions that illustrates the power of proteomics in addressing cardiovascular disease
October 31, 2022 08:00 ET
|
SomaLogic Operating Company, Inc.
BOULDER, Colo., Oct. 31, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced findings from key studies demonstrating the broad and...